Myriad Genetics to report Q3FY26 results on November 4, 2026
Myriad Genetics (NASDAQ: MYGN) will report Q3 2026 earnings on November 4, 2026, with a conference call scheduled for the same day. The company promoted Vishal Sikri to Executive Vice President - Commercial, effective September 16, 2026, following the departure of Brian Donnelly. Myriad reaffirmed its full-year 2026 financial guidance without providing updated figures.
How this was made
The 30-second read
Why it matters
The primary tradable element is the scheduled earnings catalyst plus management changes in the commercial organization. Guidance is reaffirmed for FY 2026, but the article does not provide updated guidance figures, limiting immediate directional conviction.
Market read
This is a forward-looking earnings scheduling and management-transition update that can drive pre-earnings positioning into the Nov 4 after-close print.
What to watch
The leadership transition (C-suite commercial departure and EVP promotion) could shift management tone on growth drivers, but the article does not quantify impact, so traders may need to wait for the Nov 4 commentary for actionable signals.
Background
Myriad Genetics will report Q3 2026 results on Nov 4, 2026 after market close and host a conference call the same day at 4:30 pm ET.
Ticker impact
Myriad Genetics scheduled its Q3 2026 results for Nov 4, 2026 after the close, alongside a commercial leadership transition and reaffirmed FY guidance.
Likely modest pre-earnings positioning and volatility around the Nov 4 after-close print, with direction dependent on any guidance or margin commentary changes.
The article provides a concrete earnings date and call time, plus executive promotions/departure and a guidance reaffirmation without new figures, which typically drives positioning but not a directional move by itself.
Market effects
Provides a near-term catalyst for molecular diagnostics peers via read-through on demand and commercial execution, but no sector-wide policy or regulatory change is disclosed.
No direct regional macro linkage beyond general healthcare sentiment.
Limited global relevance; the event is company-specific with no international regulatory or trial milestone mentioned.
Counterpoint
Because the company reaffirmed full-year 2026 guidance without new numbers, the earnings date may be more of a calendar catalyst than a fundamental re-rating driver.
Key entities
- companyMyriad Genetics
Molecular diagnostic testing company reporting Q3 2026 results on Nov 4, 2026 after the close.
- executiveVishal Sikri
Promoted to Executive Vice President, Commercial effective Sep 16, 2026.
- executiveBrian Donnelly
Chief Commercial Officer departing Sep 21, 2026.
- executiveSam Raha
President and CEO who commented on the commercial leadership transition.
